AFLIBERCEPT (Eylea) prior authorization at CareFirst BCBS
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
CareFirst BCBS requires Vascular Endothelial Growth Factor Inhibitor prior-authorization documentation for AFLIBERCEPT (Eylea): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
CareFirst BCBS reviews AFLIBERCEPT (Eylea) prior authorizations against its medical policy for Vascular Endothelial Growth Factor Inhibitor. CareFirst BCBS-specific context: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in Vascular Endothelial Growth Factor Inhibitor
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- CareFirst BCBS's medical policy URL referenced in the cover letter
CareFirst BCBS's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- DC/MD/VA cross-jurisdiction issues
- Step therapy on specialty drugs via CVS Caremark
- Behavioral health network adequacy
- BlueChoice HMO referral denials
AFLIBERCEPT (Eylea)-specific denial patterns and context
Across payers (not just CareFirst BCBS), AFLIBERCEPT (Eylea)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Step therapy requiring bevacizumab (Avastin off-label) first per UnitedHealthcare/Aetna policies
- Quantity limit on injections per eye per year
- High-dose Eylea HD denied (8mg formulation)
- Site-of-care reduction
Brand: Eylea. Anti-VEGF for wet AMD, DME, DR, RVO. Eylea HD (8mg, FDA-approved August 2023) enables longer dosing intervals. Biosimilars Yesafili (aflibercept-jbvf) and Opuviz (aflibercept-yszy) launched 2024.
Manufacturer patient-assistance program: EylEA4U — relevant when a CareFirst BCBS denial sticks and the patient needs bridge access while appealing.
If the PA is denied
CareFirst BCBS gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://provider.carefirst.com) with the same packet plus a peer-reviewed citation supporting AFLIBERCEPT (Eylea)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a CareFirst BCBS denial on DenialHelp.
Contact CareFirst BCBS
- Provider portal: https://provider.carefirst.com
Frequently asked questions
What documentation does CareFirst BCBS need for AFLIBERCEPT (Eylea) prior auth?
CareFirst BCBS's typical PA packet for AFLIBERCEPT (Eylea): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For Vascular Endothelial Growth Factor Inhibitor, expect clinical-criteria documentation specific to this class.
What's the turnaround time at CareFirst BCBS?
Standard AFLIBERCEPT (Eylea) PA decisions at CareFirst BCBS: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does CareFirst BCBS most often reject AFLIBERCEPT (Eylea) for?
Across CareFirst BCBS's book the common rejection patterns include: DC/MD/VA cross-jurisdiction issues; Step therapy on specialty drugs via CVS Caremark; Behavioral health network adequacy. For AFLIBERCEPT (Eylea) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with CareFirst BCBS on AFLIBERCEPT (Eylea)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the AFLIBERCEPT (Eylea) PA packet
Open ApprovalHelp — generate a AFLIBERCEPT (Eylea) prior-auth packet tailored to CareFirst BCBS's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com